福巴替尼有哪几个版本?分别多少钱?

Forbatinib is a second-generation FGFR inhibitor that provides an important treatment option for patients with cholangiocarcinoma. There are currently multiple versions of forbatinib on the market, including original drugs and generic drugs, with significant price differences. This article will introduce in detail the different versions of forbatinib, the price information of each version, and the therapeutic effect of the drug to help patients fully understand this targeted drug.

What versions of forbatinib are there

Currently, there are two versions: original drug and generic version, which are produced by different pharmaceutical companies, with obvious differences in quality and price.

Original drug version

The original drug of fobatinib is developed and produced by Taiho Oncology of Japan, with the trade name LYTGOBI. This version received accelerated approval from the US FDA in October 2022, and was approved for marketing in Japan and the EU in 2023. Original drugs have undergone strict clinical trials and quality control, and have the most complete efficacy and safety data.

Generic version

The main version of generic drugs currently on the market is produced by Laos Lucius Pharmaceuticals. The active ingredients of generic drugs are consistent with the original drugs, but the production process and quality standards may be different. Due to the elimination of research and development costs, the price of generic drugs is significantly lower than that of original drugs, providing patients with a more economical choice.

Understanding the different versions of forbatinib can help patients make the appropriate choice based on their circumstances.

How much do different versions of fobatinib cost?

The prices of various versions of fobatinib vary greatly, ranging from several thousand dollars to tens of thousands of dollars per month. Patients need to choose based on their financial status and treatment needs.

Original drug price

The original drug of Japan's Tahoe Pharmaceutical is relatively expensive, but the specific price is not yet clear.

Price of generic drugs

The specifications of generic drugs produced by Lucius in Laos are 4mg*35 tablets/box and sell for about US$480. Calculated based on the recommended dosage, the monthly treatment cost is approximately US$2,000, allowing more patients to obtain treatment opportunities.

Factors affecting price

The price of forbatinib is affected by many factors, including research and development costs, production processes, market demand, etc. The higher price of the original drug is mainly due to the huge investment in research and development in the early stage. Generic drugs omit the research and development process and are mostly produced in countries with lower labor costs, so they have obvious price advantages.

Price is an important consideration when choosing a forbatinib version, and patients should weigh efficacy and affordability.

Therapeutic effect of fobatinib

As a second-generation FGFR inhibitor, fobatinib has shown significant efficacy in the treatment of drug-resistant cholangiocarcinoma, providing new hope for patients.

Effectiveness of targeted therapy

Forbatinib effectively blocks the proliferation signaling of tumor cells by selectively inhibiting FGFR tyrosine kinase activity. Clinical studies have shown that forbatinib can still exert significant anti-tumor effects in patients who have developed resistance after treatment with first-generation FGFR inhibitors.

Clinical data

Key clinical trials show that the objective response rate of forbatinib in the treatment of patients with FGFR2 fusion/rearranged cholangiocarcinoma reached 42%, and the median progression-free survival was 9.0 months. These data are significantly better than traditional chemotherapy regimens and bring substantial survival benefits to patients with advanced cholangiocarcinoma.

Safety performance

The most common adverse reactions of forbatinib include hyperphosphatemia and ocular toxicity, but most are grade 1-2 and can be controlled through dose adjustment and management. Compared with chemotherapy, its hematological toxicity is significantly reduced and better tolerated by patients.

Forbatinib provides an efficient and precise treatment option for patients with cholangiocarcinoma with abnormal FGFR genes, significantly improving the treatment prospects of this type of refractory tumors.